Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy

• DOI: 10.2147/ott.s140118
• Publication Date: 2017-08-10T21:30:14Z
• Authors: Li Chen; Ying Hao; Lihua Zhu; Sen Li; Yanjiao Zuo; Yuxin Zhang; Hongjiang Song; Yingwei Xue
• Keywords: Univariate analysis; Regimen; Chemotherapy regimen

Currently, precise predictors in gastric cancer patients undergoing neoadjuvant chemotherapy are lacking. The study aims to investigate the prognostic value of monocyte lymphocyte ratio (MLR) with advanced receiving S-1 plus oxaliplatin (SOX) or and capecitabine (XELOX) regimen.The data from Harbin Medical University Cancer Hospital August 2008 September 2015 were retrospectively collected. Ninety-one treated included. blood samples collected before chemotherapy. MLR was divided into two groups: Low-MLR <0.27 group high-MLR ≥0.27 group. Survival curves performed using Kaplan-Meier method compared log-rank test. Univariate multivariate Cox proportional hazards regression model evaluated determine independent factors.The univariate analysis showed that median disease free survival (DFS) overall (OS) for all better low-MLR than (median DFS 26.80 23.73 months, P=0.653, respectively; OS 27.93 26.87 P=0.807, respectively). Multivariate level not an factor OS. Nevertheless, low values those high 30.23 21.03 P=0.645, 37.97 25.83 P=0.509, respectively); (P=0.624) 26.37 (P=0.584) respectively. However, had 5-year rates.MLR may be used as a convenient cheap marker SOX XELOX. Low help doctors terms efficient measures treat cancer.